Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-26
2011-04-26
Pitrak, Jennifer (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C435S006120, C435S375000
Reexamination Certificate
active
07932234
ABSTRACT:
CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy.
REFERENCES:
patent: 5417978 (1995-05-01), Tari et al.
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5855911 (1999-01-01), Lopez-Berestein et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5994320 (1999-11-01), Low et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: 6451991 (2002-09-01), Martin et al.
patent: 2003/0045488 (2003-03-01), Brown et al.
patent: 2003/0087857 (2003-05-01), Freier
patent: 2003/0158143 (2003-08-01), Gleave et al.
patent: WO 92/03470 (1992-03-01), None
patent: WO 92/03471 (1992-03-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 00/78341 (2000-12-01), None
patent: WO 01/05435 (2001-01-01), None
patent: WO 02/22642 (2002-03-01), None
patent: WO 03/030826 (2003-04-01), None
patent: WO 03/062421 (2003-07-01), None
Kalota, et al. (2006) Progress in the Development of Nucleic Acid Therapeutics. Handbook Exp. Pharm. v.173:173-196.
Crooke (2004) Progress in Antisense Technology. Ann. Rev. Med. v. 55:61-9.
Wen, P.Y., and J.S. Loeffler (2000) (Abstract Only) Brain Metastases. Curr. Treat. Options Oncol., v.1(5):447-58.
Zumkeller, W. (2002) IGFs and IGF-Binding Proteins as Diagnostic Markers and Biological Modulators in Brain Tumors. Expert Rev. Mol. Diagn., v.2(5):473-7.
Opalinska and Gerwitz (2002) Nucleic Acid Terhapeutics: Basic Principles and Recent Applications. Nature Reviews Drug Discovery, v.1:503-14.
Kalota, et al. (2006) Progress in the Development of Nucleic Acid Therapeutics. H.E.P. v.173:173-96.
IGFBP alignment [online]. [retrieved on Jun. 18, 2009]. Retrieved from the internet: <http://blast.ncbi.nlm.nih.gov/Blast.cgi>.
Norqvist, et al. (2002) Expression of IGF-II, IGFBG-2, -5, and -6 in Meningiomas With Different Brain Invasiveness. J. Neuro-Onc., v.57:19-26.
Wang, et al. (2006) Overexpression of IGFBP5, But Not IGFBP3, Correlates With the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study. Technology in Cancer Research and Treatment, V.5(3):195-9.
Moore, et al. (2009) IGFBP2 Is a Candidate Biomarker for INK4A-ARF Status and a Therapeutic Target for High-Grade Gliomas. Proc. Nat. Acad. Sci., v.106(39):16675-9.
Lin, et al. (2009) Plasma IGFBP-2 Levels Predict Clinical Outcomes of Patients With High-Grade Gliomas. Neuro Oncol., v.11(5):468-76.
Binkert, et al., Structure of the Human Insulin-Like Growth Factor Binding Protein-2 Gene, Molecular Endocrinology, 1992, pp. 826-836, vol. 6, No. 5.
Bubendorf, et al., Hormone Therapy Failure in Human Prostate Cancer. Analysis by Complementary DNA and Tissue Microarrays, Journal of the National Cancer Institute, Oct. 20, 1999, pp. 1758-1764, vol. 91, No. 20.
Corkins et al., Growth Stimulation by Transfection of Intestinal Epithelial Cells with an Antisense Insulin-Like Growth Factor Binding Protein-2 Construct, Biochemical and Biophysical Research Communications, Jun. 26, 1995, pp. 707-713, vol. 211, No. 3.
Forsyth, et al., Growth Inhibition of a Human Colon Cancer Cell Line by Antisense Oligonucleotide to IGFBP-2, 1995, pp. A726, vol. 108, No. 4.
Gleave, et al., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, pp. 209-221, vol. 4, No. 3.
Miyake, et al., Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models, Cancer Research, Jun. 1, 2000, pp. 3058-3064, vol. 60.
Steller et al., Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells, Proc. Natl. Acad. Sci.-Cell Biology, Dec. 1995, pp. 11970-11974, vol. 92.
Wang et al., Correlation of Glioma Cell Regression with Inhibition of Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein-2 Expression, Neuroendrocrinology, 1997, pp. 203-211, vol. 66.
Andress et al. , Human Osteoblast-derived Insulin-like Growth Factor (IGF) Binding Protein-5 Stimulates Osteoblast Mitogenesis and Potentiates IGF Action, Journal of Biological Chemistry Nov. 5, 1992, pp. 22467-22472, vol. 267, No. 31.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, Feb. 1998, pp. 45-50.
Crooke et al., Basic Principles of Antisense Therapeutics, Antisense Research and Application, 2004, pp. 1-50, Publisher: Springer.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, pp. 307-319, vol. 18.
Opalinska et al., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, Jul. 2002, pp. 503-514, vol. 1.
Agrawal et al., Antisense therapeutics: is it as simple as complementary base recognition?, Molecular Medicine Today, Feb. 2000, pp. 72-81, vol. 6.
Angelloz-Nichoud et al., Autocrine Regulation of Cell Proliferation by the Insulin-Like Growth Factor (IGF) and IGF Binding Protein-3 Protease System in a Human Prostate Carcinoma Cell Line (PC-3), Endocrinology, 1995, pp. 5485-5492, vol. 136, No. 12.
Boudon et al., Secretion of Insulin-Like Growth Factors and Their Binding Proteins by Human Normal and Hyperplastic Prostatic Cells in Primary Culture, Journal of Clinical Endocrinology and Metabolism, Feb. 1, 1996, pp. 612-617, vol. 81, No. 2.
Cucco et al., In Vitro and in Vivo Reversal of Multidrug Resistance in a Human Leukemia-resistant Cell Line by mdr1Antisense Oligodeoxynucleotides, Cancer Research, Oct. 1, 1996, pp. 4332-4337, vol. 56.
Elgin et al., An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I, Cell Biology, May 1987, pp. 3254-3258, vol. 84, Publisher: Proc. Natl. Acad. Sci.
Figueroa et al., Differential Expression of Insulin-Like Growth Factor Binding Proteins in High Versus Low Gleason Score Prostate Cancer, The Journal of Urology, Apr. 1998, pp. 1379-1383, vol. 159, No. 4.
Huynh et al., Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells, The Journal of Biological Chemistry, Jan. 12, 1996, pp. 1016-1021, vol. 271, No. 2.
Jansen et al., bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice, Nature Medicine, Feb. 1998, vol. 4, No. 2.
Monia et al., Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted against C-raf Kinase, Nature Medicine, Jun. 1996, pp. 668-675, vol. 2, No. 6.
Nickerson et al., Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5, Endocrinology, 1998, pp. 807-810, vol. 139, No. 2.
Oh et al., Mangagement of Hormone Refractory Prostate Cancer: Current Standards and Future Prospects, The Journal of Urology, Oct. 1998, pp. 1120-1229, vol. 160, No. 4.
Oh et al., Insulin-like Growth Factor (IGF)-independent Action of IGF-binding Protein-3 in Hs578T Human Breast Cancer Cells, The Journal of Biological Chemistry, Jul. 15, 1993, pp. 14964-14971, vol. 268, No. 20.
Rajaram, Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions, Endocrine Reviews, 1997, pp. 801-831, vol. 18, No. 6.
Damon, et al., Overexpression of an Inhibitory Insulin-Like Growth Factor Binding Protein (IGFBP), IGFBP-4, Delays Onset of Prostate Tumor Formation, Endocrinology, 1998, pp. 3456-3464, vol. 139, No. 8.
Ziegler et al., Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targe
Gleave Martin E.
Levitt Randy J.
Pollak Michael N.
Larson & Anderson LLC
Pitrak Jennifer
The University of British Columbia
LandOfFree
Bispecific oligonucleotide for the treatment of CNS... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific oligonucleotide for the treatment of CNS..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific oligonucleotide for the treatment of CNS... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630012